According to the Zhitong Finance App, Prorow Pharmaceutical (000739.SZ) issued an announcement. Recently, Zhejiang Puluo Jiayuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the European Pharmacopeia Suitability Certificate for Gabapentin APIs (“CEP Certificate”) issued by the European Medicines Quality Administration (EDQM). Gabapentin is an artificially synthesized amino acid similar to the neurotransmitter gamma-aminobutyric acid (GABA). Indications are: 1. Neuralgia after herpes infection: for the treatment of post-herpetic neuralgia in adults; 2. Epilepsy: for adjuvant treatment of partial seizures with or without secondary generalized seizures in adults and children aged 12 and over; it can also be used as adjuvant treatment for partial seizures in children aged 3 to 12.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.